ArticleAIDS (London, England)2026

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.

James Mason et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.